Neurotech International Ltd

NTI

Company Profile

  • Business description

    Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.

  • Contact

    55 Collins Street
    Suite 102, Level 1
    MelbourneVIC3000
    AUS

    T: +61 394983132

    https://www.neurotechinternational.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    18

Stocks News & Analysis

stocks

ASX gold miner under pressure to sell by activist investor

Activist investor presses gold miner on selling to larger players.
stocks

Ask the Analyst: Will Amcor lose its dividend aristocrat status?

When consistency becomes constraint.
stocks

Chart of the Week: We see opportunity in this beaten down industrial player

The market sees risks and are discounting the shares excessively.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,916.9058.60-0.65%
CAC 408,216.1165.690.81%
DAX 4024,921.29125.350.51%
Dow JONES (US)51,384.26697.191.38%
FTSE 10010,334.472.170.02%
HKSE25,253.40379.81-1.48%
NASDAQ26,691.50162.48-0.61%
Nikkei 22567,470.69931.45-1.36%
NZX 50 Index13,101.6113.47-0.10%
S&P 5007,553.190.49-0.01%
S&P/ASX 2008,686.1059.50-0.68%
SSE Composite Index4,057.7826.19-0.64%

Market Movers